NOD样受体蛋白3炎性小体抑制剂在疾病治疗中的潜力
The Potential of NOD-like Receptor Protein 3 Inflammasome Inhibitors in the Treatments of Diseases.
作者信息
Abdel-Magid Ahmed F
机构信息
Therachem Research Medilab, LLC, 100 Jade Park, Chelsea, Alabama 35043, United States.
出版信息
ACS Med Chem Lett. 2023 Sep 18;14(10):1323-1325. doi: 10.1021/acsmedchemlett.3c00378. eCollection 2023 Oct 12.
The invention in this patent application relates to 4-aminopyridazin-6-one derivatives represented generally by formula 1. These compounds are inhibitors of the NOD-like receptor protein 3 (NLRP3) inflammasome pathway and may potentially provide a useful treatment for one or more of the diseases and disorders mediated by NLRP3, including but not limited to immune diseases, inflammatory diseases, autoimmune diseases, autoinflammatory fever syndromes, cryopyrin-associated periodic syndrome, chronic liver disease, kidney-related disease, hyperoxaluria, lupus nephritis, Type I and Type II diabetes, nephropathy, neurodegenerative diseases, Alzheimer's disease, cardiovascular diseases, metabolic diseases and many more.
本专利申请中的发明涉及一般由式1表示的4-氨基哒嗪-6-酮衍生物。这些化合物是NOD样受体蛋白3（NLRP3）炎性小体途径的抑制剂，并且可能为一种或多种由NLRP3介导的疾病和病症提供有效的治疗方法，包括但不限于免疫疾病、炎性疾病、自身免疫疾病、自身炎症性发热综合征、冷吡啉相关周期性综合征、慢性肝病、肾脏相关疾病、高草酸尿症、狼疮性肾炎、I型和II型糖尿病、肾病、神经退行性疾病、阿尔茨海默病、心血管疾病、代谢疾病等等。
Zotero 插件